Company
Paradigm Biopharmaceuticals Limited
Headquarters: Melbourne, VIC, Australia
CEO: Dr. Donna L. Skerrett M.D., MS
Market Cap
A$107.0 Million
AUD as of July 1, 2024
US$71.3 Million
Paradigm Biopharmaceuticals Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Stocks & Indices
Paradigm Biopharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: PAR wb_incandescent